Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2022

17-10-2021 | Endoscopy | Original Article

Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer

Authors: Monika Laszkowska, Han Truong, Adam S. Faye, Judith Kim, Sarah Xinhui Tan, Francesca Lim, Julian A. Abrams, Chin Hur

Published in: Digestive Diseases and Sciences | Issue 8/2022

Login to get access

Abstract

Background and Aims

Guidelines cite extensive gastric intestinal metaplasia (GIM) as a bigger risk factor for gastric cancer (GC) than limited GIM and an indication for endoscopic surveillance. Data on progression of extensive GIM to GC in the USA are limited. This study aimed to estimate the prevalence and progression rates of extensive GIM in a US cohort.

Methods

This retrospective study assessed the prevalence of extensive GIM between 1/1/1990 and 8/1/2019 at a large academic medical center. Multivariable regression was used to identify predictors of extensive GIM. Incidence of GC on follow-up was calculated as number of new diagnoses divided by person-years of follow-up. Presence of GIM on subsequent follow-up endoscopy was assessed.

Results

Of 1256 individuals with GIM, 352 (28%) had extensive GIM and 904 (72%) had limited GIM. On multivariable analysis, older age (OR 1.01, 95% CI 1.00–1.02) and Hispanic ethnicity (OR 1.55, 95% CI 1.11–2.16) were predictive of extensive GIM. The annual incidence of GC for GIM overall was 0.09%. There was no difference in progression to GC between extensive or limited GIM (IRR 0, 95% CI 0–2.6), or to advanced lesions overall (IRR 0.37, 95% CI 0.04–1.62). 70% of individuals had persistent GIM on follow-up biopsy, and 22% with limited GIM had extensive GIM on follow-up biopsy.

Conclusions

28% of individuals with GIM have the extensive subtype, and are more likely to be older and of Hispanic ethnicity. There was no difference in progression to GC between extensive and limited GIM. Further research is needed to better assess risk of GIM in the US context.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cronin KA, Lake AJ, Scott S et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2018;124:2785–2800.CrossRef Cronin KA, Lake AJ, Scott S et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2018;124:2785–2800.CrossRef
2.
go back to reference SEER Cancer Stat Facts: Stomach Cancer. National Cancer Institute. SEER Cancer Stat Facts: Stomach Cancer. National Cancer Institute.
3.
go back to reference Choi KS, Jun JK, Suh M et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea. Br J Cancer. 2015;112:608–612.CrossRef Choi KS, Jun JK, Suh M et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea. Br J Cancer. 2015;112:608–612.CrossRef
4.
go back to reference Altayar O, Davitkov P, Shah SC et al. AGA technical review on gastric intestinal metaplasia—epidemiology and risk factors. Gastroenterology. 2020;158:732.e16-744.e16.CrossRef Altayar O, Davitkov P, Shah SC et al. AGA technical review on gastric intestinal metaplasia—epidemiology and risk factors. Gastroenterology. 2020;158:732.e16-744.e16.CrossRef
5.
go back to reference Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493–498.CrossRef Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493–498.CrossRef
6.
go back to reference Zhang X, Li M, Chen S et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: A meta-analysis and systematic review. Gastroenterology. 2018;155:347-354.e9.CrossRef Zhang X, Li M, Chen S et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: A meta-analysis and systematic review. Gastroenterology. 2018;155:347-354.e9.CrossRef
7.
go back to reference Shah SC, Gawron AJ, Li D. Surveillance of gastric intestinal metaplasia. Am J Gastroenterol. 2020;115:641–644.CrossRef Shah SC, Gawron AJ, Li D. Surveillance of gastric intestinal metaplasia. Am J Gastroenterol. 2020;115:641–644.CrossRef
8.
go back to reference Shah SC, Gawron AJ, Mustafa RA et al. Histologic subtyping of gastric intestinal metaplasia: Overview and considerations for clinical practice. Gastroenterology. 2020;158:745–750.CrossRef Shah SC, Gawron AJ, Mustafa RA et al. Histologic subtyping of gastric intestinal metaplasia: Overview and considerations for clinical practice. Gastroenterology. 2020;158:745–750.CrossRef
9.
go back to reference Marcos P, Brito-Gonçalves G, Libânio D et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West? Gut. 2020;69:1762–1768.CrossRef Marcos P, Brito-Gonçalves G, Libânio D et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West? Gut. 2020;69:1762–1768.CrossRef
10.
go back to reference Bisschops R, Areia M, Coron E et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. Endoscopy. 2016;48:843–864.CrossRef Bisschops R, Areia M, Coron E et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. Endoscopy. 2016;48:843–864.CrossRef
11.
go back to reference Park WG, Shaheen NJ, Cohen J et al. Quality indicators for EGD. Gastrointest Endosc. 2015;81:17–30.CrossRef Park WG, Shaheen NJ, Cohen J et al. Quality indicators for EGD. Gastrointest Endosc. 2015;81:17–30.CrossRef
12.
go back to reference Sharma P, Parasa S, Shaheen N. Developing quality metrics for upper endoscopy. Gastroenterology. 2020;158:9–13.CrossRef Sharma P, Parasa S, Shaheen N. Developing quality metrics for upper endoscopy. Gastroenterology. 2020;158:9–13.CrossRef
13.
go back to reference Song H, Ekheden IG, Zheng Z et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ Br Med J. 2015;351:h3867.CrossRef Song H, Ekheden IG, Zheng Z et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ Br Med J. 2015;351:h3867.CrossRef
14.
go back to reference Huang RJ, Ende AR, Singla A et al. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. Gastrointest Endosc. 2020;91:70-77.e1.CrossRef Huang RJ, Ende AR, Singla A et al. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. Gastrointest Endosc. 2020;91:70-77.e1.CrossRef
15.
go back to reference Fennerty MB, Emerson JC, Sampliner RE et al. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. Cancer Epidemiol Biomark Prev. 1992;1:293–296. Fennerty MB, Emerson JC, Sampliner RE et al. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. Cancer Epidemiol Biomark Prev. 1992;1:293–296.
16.
go back to reference Sonnenberg A, Genta RM. Changes in the gastric mucosa with aging. Clin Gastroenterol Hepatol. 2015;13:2276–2281.CrossRef Sonnenberg A, Genta RM. Changes in the gastric mucosa with aging. Clin Gastroenterol Hepatol. 2015;13:2276–2281.CrossRef
18.
go back to reference Gupta S, Li D, El Serag HB et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158:693–702.CrossRef Gupta S, Li D, El Serag HB et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158:693–702.CrossRef
19.
go back to reference Pimentel-Nunes P, Libanio D, Marcos-Pinto R et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365–388.CrossRef Pimentel-Nunes P, Libanio D, Marcos-Pinto R et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51:365–388.CrossRef
20.
go back to reference Banks M, Graham D, Jansen M et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68:1545–1575.CrossRef Banks M, Graham D, Jansen M et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68:1545–1575.CrossRef
21.
go back to reference Reddy KM, Chang JI, Shi JM et al. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. Clin Gastroenterol Hepatol. 2016;14:1420–1425.CrossRef Reddy KM, Chang JI, Shi JM et al. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. Clin Gastroenterol Hepatol. 2016;14:1420–1425.CrossRef
23.
go back to reference Li D, Bautista MC, Jiang SF et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016;111:1104–1113.CrossRef Li D, Bautista MC, Jiang SF et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016;111:1104–1113.CrossRef
24.
go back to reference Tan MC, Mallepally N, Liu Y et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol. 2020;115:381–387.CrossRef Tan MC, Mallepally N, Liu Y et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol. 2020;115:381–387.CrossRef
25.
go back to reference Nguyen TH, Tan MC, Liu Y et al. Prevalence of gastric intestinal metaplasia in a multiethnic US veterans population. Clin Gastroenterol Hepatol. 2020;19:269–276.CrossRef Nguyen TH, Tan MC, Liu Y et al. Prevalence of gastric intestinal metaplasia in a multiethnic US veterans population. Clin Gastroenterol Hepatol. 2020;19:269–276.CrossRef
26.
go back to reference Shichijo S, Hirata Y, Niikura R et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016;84:618–624.CrossRef Shichijo S, Hirata Y, Niikura R et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016;84:618–624.CrossRef
27.
go back to reference Gawron AJ, Shah SC, Altayar O et al. AGA technical review on gastric intestinal metaplasia—natural history and clinical outcomes. Gastroenterology. 2020;158:705.e5-731.e5.CrossRef Gawron AJ, Shah SC, Altayar O et al. AGA technical review on gastric intestinal metaplasia—natural history and clinical outcomes. Gastroenterology. 2020;158:705.e5-731.e5.CrossRef
28.
go back to reference Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer. 2000;3:9–18.CrossRef Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer. 2000;3:9–18.CrossRef
29.
go back to reference Mizoue T, Yoshimura T, Tokui N et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer. 2003;106:103–107.CrossRef Mizoue T, Yoshimura T, Tokui N et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer. 2003;106:103–107.CrossRef
30.
go back to reference Choi KS, Jun JK, Park E-C et al. Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One. 2012;7:e50041–e50041.CrossRef Choi KS, Jun JK, Park E-C et al. Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One. 2012;7:e50041–e50041.CrossRef
31.
go back to reference Jung KW, Won YJ, Kong HJ et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46:109–123.CrossRef Jung KW, Won YJ, Kong HJ et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014;46:109–123.CrossRef
32.
go back to reference Kim GH, Bang SJ, Ende AR et al. Is screening and surveillance for early detection of gastric cancer needed in Korean Americans? Korean J Intern Med. 2015;30:747–758.CrossRef Kim GH, Bang SJ, Ende AR et al. Is screening and surveillance for early detection of gastric cancer needed in Korean Americans? Korean J Intern Med. 2015;30:747–758.CrossRef
33.
go back to reference Cho E, Kang MH, Choi KS et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev. 2013;14:2533–2540.CrossRef Cho E, Kang MH, Choi KS et al. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev. 2013;14:2533–2540.CrossRef
34.
go back to reference Kobayashi K, Mine T. Cost-effective analysis of gastric cancer screening in Japan. Gastrointest Endosc. 2004;59:P137.CrossRef Kobayashi K, Mine T. Cost-effective analysis of gastric cancer screening in Japan. Gastrointest Endosc. 2004;59:P137.CrossRef
Metadata
Title
Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer
Authors
Monika Laszkowska
Han Truong
Adam S. Faye
Judith Kim
Sarah Xinhui Tan
Francesca Lim
Julian A. Abrams
Chin Hur
Publication date
17-10-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07276-9

Other articles of this Issue 8/2022

Digestive Diseases and Sciences 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.